AUSTIN, Texas, March 3, 2015 (GLOBE NEWSWIRE) -- LDR Holding Corporation (Nasdaq:LDRH), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, announced today that it has entered into a worldwide distribution agreement with Sentio, LLC to distribute the SentioMMG® nerve mapping system. SentioMMG smart-sensors employ accelerometer technology to sensitively measure when muscle contraction occurs, as a means to alert surgeons of motor nerve location.
Sentio offers a patented nerve location technology facilitating minimally invasive access to the spine. It is intended to locate and map motor nerve roots and their peripheral extensions originating from spinal levels C3-T1 and L2-S2.
"LDR's Avenue® L lateral lumbar cage with VerteBRIDGE® plating technology is an innovative spinal construct featuring a lumbar cage optimized for placement via a lateral approach and integrated plate fixation that can be inserted without requiring additional exposure," said Sean Parker, Vice President of Market Development for Sentio. "Adding SentioMMG to the LDR product portfolio completes the offering, makes the entire procedure highly efficient, and delivers full control to the operative surgeon."
"Providing safe and efficient access is a key aspect to LDR's success in the lateral lumbar market," commented Joe Ross, LDR's Executive Vice President of Global Marketing. "Our partnership with Sentio addresses that need and demonstrates our dedication to bringing innovative technologies to spine surgeons and their patients. We are very excited to offer SentioMMG through our LDR sales network."
About Sentio, LLC
SentioMMG smart-sensors employ a proprietary technology, using non-invasive accelerometer-based sensors to measure MMG (mechanomyography) activity, or the mechanical "twitch" associated with muscle contraction. The result is an intuitive, surgeon-directed tool for establishing safe access in a variety of surgical applications.
Sentio is currently cleared for use in the United States by the FDA to assist in locating and mapping motor nerves through the use of mechanomyographic signals and electrical stimulus of nerves. SentioMMG has a CE mark for use in the European Union and other markets.
About LDR Holding
LDR Holding Corporation is a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders. LDR's primary products are based on its exclusive Mobi® non-fusion and VerteBRIDGE® fusion technology platforms and are designed for applications in the cervical and lumbar spine. These technologies are designed to enable products that are less invasive, provide greater intra-operative flexibility, offer simplified surgical techniques and promote improved clinical outcomes for patients as compared to existing alternatives. In August 2013, LDR received approval from the U.S. Food and Drug Administration (FDA) for the Mobi-C cervical disc replacement device, the first and only cervical disc replacement device to receive FDA approval to treat both one-level and two-level cervical disc disease. For more information regarding LDR Holding and the Mobi-C Cervical Disc, visit www.ldr.com or www.cervicaldisc.com.
Avenue L Indications for Use
The Avenue® L Lateral Lumbar Cage is cleared by FDA in the United States for intervertebral body fusion of the lumbar spine, from L2 to S1, in skeletally mature patients who have had six months of non-operative treatment. The device is intended for use at either one level or two contiguous levels for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. The device system is designed for use with or without integrated fixation and must be used in conjunction with posterior supplemental fixation (e.g., pedicle screws). The device system is intended for use with autograft to facilitate fusion.
LDR Forward-Looking Statements
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief or current expectations of LDR and members of its management team with respect to LDR's future business operations as well as the assumptions upon which such statements are based. Factors that could cause actual results to differ materially from those contemplated within this press release can also be found in LDR's Risk Factors disclosure in its Annual Report on Form 10-K, filed on February 20, 2015, and in LDR's other filings with the SEC. LDR disclaims any responsibility to update any forward-looking statements.
©2015 LDR Holding Corporation, All Rights Reserved